Novavax Nuvaxovid COVID-19 vaccine approved in Canada for ages 12-17

Novavax announced that Health Canada has approved a supplement to a New Drug Submission for Nuvaxovid for active immunization to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 as a primary series of two doses in adolescents aged 12 through 17.